Abstract
Phase 1 Study of CA-4948, a Novel Inhibitor of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) in Patients with R/R Non-Hodgkin Lymphoma (NHL)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have